Home > Insider Trading > Filing (0001209191-23-006422)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1438533	Travere Therapeutics Inc.	TVTX	Pharmaceutical Preparations (2834)	262383102

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1943192	R. Christopher Cline	C/O Travere Therapeutics, Inc. 3611 Valley Centre Drive, Ste 300 San Diego CA 92130	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-31	20,250	$0.00	53,121	No	4	A	Direct
Common Stock	Disposition	2023-02-01	1,588	$21.75	51,533	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee stock option (right to buy)	Acquisiton	2023-01-31	54,500	$0.00	54,500	$22.40
Common Stock	Performance-based restricted stock units	Acquisiton	2023-01-31	6,750	$0.00	6,750	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
54,500		2033-01-30	No	4	A	Direct
6,750			No	4	A	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.